For example, overall mortality was 48% in a cohort of 187 symptomatic patients with MCAD (25%); LCHAD (22%); VLCAD (19%); or CPT-1, CACT, and CPT-2 (19%) deficiencies aged <6 years at diagnosis (between 1977 and 2009).53 Survival rate was significantly less favorable with younger age at disease onset, and with certain defects such as CACT deficiency (mortality: 92%) compared with other disorders such as MCAD deficiency (mortality: 20%). This evidence concerns the gene SLC25A20 and medium chain acyl-CoA dehydrogenase deficiency.